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Wolfram Sterry1 and Peter Walden1
Mutator phenotypes with microsatellite instability (MSI) correlated with defects in the mismatch repair system
are characteristic for a subset of solid neoplasms, but are rare in non-Hodgkin lymphomas. In mismatch repair-
deficient mice, however, mutator-type non-Hodgkin lymphomas are the most frequent tumors. To determine
the role of MSI in mycosis fungoides, we compared the states of the eight dinucleotide microsatellite loci
DXS418, DXS453, DXS556, DXS1060, D1S201, D6S260, D9S162, and D10S215 in tumor cells of 12 well-characterized
patients at early- and advanced-stage diseases to matched healthy tissue. We did not find any MSI, although all
but one patient had progressed to advanced-stage disease within the timeframe of the study. Concordantly, the
expression of mismatch repair genes was normal. These results suggest that progressive accumulation of
mutations as detected by MS analysis does not play a major role in the pathogenesis or in the progression of
mycosis fungoides.
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INTRODUCTION
Cutaneous T-cell lymphomas (CTCL) are clonal lymphopro-
liferative malignancies with primary manifestation on the
skin. The most frequent subtype is mycosis fungoides (MF). In
more than 60% of cases, patients with MF present initially
with patches and/or plaques (Kim et al., 1999) microscopi-
cally characterized by epidermotropic atypical lymphocytes
with cytological and immunophenotypic characteristics of
normal mature T lymphocytes (Santucci et al., 2000). At these
early stages, the patients respond well to common skin-
directed therapies such as psoralen plus UVA irradiation and
experience indolent clinical courses with a 5-year survival
rate of around 87% (Zackheim et al., 1999; Kim et al., 2003).
With disease progression to advanced stages, the malignant
lymphocytes lose their epidermotropism, may undergo
anaplastic transformation, and may disseminate to lymph
nodes, blood, and visceral organs (Diamandidou et al.,
1998). Patients with advanced MF are often refractory to
therapy and have a poor prognosis with a 5-year survival rate
of around 40% (de Coninck et al., 2001).
Despite many efforts, the molecular events involved in the
pathogenesis of MF and transformation of the tumor and
tumor cells during disease progression remain obscure.
Several publications report high chromosomal instability
evidenced by heterogeneous patterns of extensive chromo-
somal aberrations (Kaltoft et al., 1992; Karenko et al., 1997,
2003; Mao et al., 2002; Fischer et al., 2004). But also
accumulating mutations at the gene level may contribute to
the pathogenesis of MF. Such progressive genetic defects
have been amply demonstrated in hereditary colon carci-
noma and correlated with DNA mismatch repair defects and
microsatellite instability (MSI) (Bronner et al., 1994; Boland
et al., 1995; Dietmaier et al., 1997, 1999; Ko¨lble et al., 1999;
Tsao et al., 1999). Mismatch repair gene knockout mice
notoriously develop lymphoid neoplasm (de Wind et al.,
1998), and recent reports suggest that MSI may play a role
in the pathogenesis of hematological malignancies in man
as well (Gartenhaus et al., 1996; Pabst et al., 1996; Sanz-
Vaque et al., 2001; Niv et al., 2005). MSI is characterized
by alterations in the numbers of microsatellite repeats
(Peltomaki, 2003). Most of these mutations occur in non-
coding DNA that makes up 98% of the human genome, and
have no effect. Some, however, occur within coding regions
and cause frame shifts, leading to stop codons and truncated
gene products that, predictably, are non-functional (Lengauer
et al., 1997). If such mutations affect tumor suppressor genes
(e.g., p53), they may contribute to initiation and/or progres-
sion of malignant developments (Boland et al., 1995).
Extrapolating the earlier studies with colon cancers to
cutaneous lymphoma, Scarisbrick et al. (2003) have investi-
gated the occurrence and frequency of MSI in tumor stage MF
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and Ru¨bben et al. (2004)have investigated MSI in subclone
differentiation of the tumor cells. In their study, Scarisbrick
et al. established a panel of MS markers (‘‘CTCL panel’’),
which showed a higher detection rate of MSI in comparison
with the primer panel used for the hereditary nonpolyposis
colorectal cancer (22 vs 16%, respectively). With this work,
we opted to determine in a longitudinal study the frequency
and prognostic value of MSI in the progression of MF from
early to advanced stages. To this end, we analyzed and
compared the states of eight microsatellite loci, including the
two most sensitive markers of each of the two studies by
Scarisbrick and Ru¨bben et al., in tumor lesions and peripheral
blood of 12 patients at different stages of disease with
indolent or aggressive clinical courses. The results were
correlated with the expression of the mismatch repair gene
products and compared to the chromosome statuses pre-
viously determined by comparative genomic hybridization.
RESULTS
Clinical courses
The 12 patients (eight male and four female) included in the
study had been unequivocally diagnosed for MF by standard
clinical, histopathological, and molecular genetic criteria
(Willemze et al., 2005). Their ages at the beginning of the
observation period ranged between 47 and 88 years with a
median of 62.6 years. The times of clinical follow-up and for
analyzing tumor biopsies for molecular genetic alterations
covered 2–7 years, 3.8 years on average. Age, sex, and
clinical characteristics of the patients, including disease
stage, treatment modalities, and outcome at the time of the
last examination for this report are summarized in Table 1
ordered according to the TNM stage. One patient (patient 12)
had tumor-stage MF at the beginning of the study, six patients
(patients 2, 4, 5, 6, 9, and 10) progressed during the study
from patch or plaque-stage to tumor-stage MF. In four
patients (patients 3, 7, 8, and 11), the disease advanced from
patch to plaque stage and in one patient (patient 1) it
remained in patch stage. The patients had received different
therapies according to their tumor stage. All patients did
respond at least partially to at least one of the therapies during
this period. The clinical outcome for the patients at the last
follow-up and after the last indicated treatment was as
follows: three patients were in complete remission, six had
partial remission or stable disease, two had progressive
lymphoma, and one had died of disease. In summary, 11 of
the 12 patients experienced significant progression of their
disease during the observation period, with seven being in
tumor-stage disease at the end of the follow-up. All patients
had received, at some time, treatments that can potentially
cause mutations, and all responded temporarily to at least
one of the therapies, implying therapy-related selective
pressure on the development of the tumor cells.
Microsatellite states in MF tumor cells
Eight marker microsatellites were analyzed (Table 2), four
located on the X chromosome producing monoallelic
amplificates in male patients, and one each on autosomes
1, 6, 9, and 10. The former four markers were chosen
because they had been found to be more sensitive indicators
of MSI than the consensus panel used for hereditary non-
polyposis colon cancers (Tsao et al., 1999), and the latter four
because of their special relevance for CTCL (Scarisbrick et al.,
2000, 2003; Ru¨bben et al., 2004). For every patient, two or
three tumor samples were analyzed, that is, biopsies taken
from MF skin lesions at the initial presentation and at later,
advanced disease stages. Controls were peripheral blood
mononuclear cells of the same patients. PCR with limited
numbers of tumor cells together with an excess of other cells
Table 1. Clinical characteristics of the cases
Patient Age1 Sex Stage2 Treatments Clinical outcome
1 72 F T1N0M0 PUVA, local steroids CR
2 66 F T1N0M0 INF-a+PUVA, radiation PR
3 68 M T2N0M0 PUVA+INF-a CR
4 68 M T2N0M0 PUVA+INF-a PR
5 62 M T2N0M0 PUVA, INF-a, acitretin, MTX PR
6 57 F T3N0M0 PUVA, PUVA+INF-a, denileukin-difitox CR
7 69 M T3N0M0 PUVA, PUVA+INF-a, PR
8 31 M T3N0M0 PUVA, radiatio, PUVA+INF-a PR
9 65 M T3N0M0 PUVA, INF, MTX, bexarotene, radiatio PD
10 59 M T3N0M0 PUVA, radiatio PD
11 83 F T3N1M0 PUVA, radiatio, doxorubicine, MTX PR
12 51 M T3N1M0 Doxorubicine, radiatio, PUVA+INF-a, CHOP PD, DOD
1Age: age at initial presentation.
2Stage according to Bunn and Lamberg at initial presentation.
3Clinical outcomes at final follow-up this study. CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; DOD: died of
disease.
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is highly prone to producing artifacts (Sieben et al., 2000;
Diaz-Cano, 2001). The cell numbers in early-stage MF
lesions, especially in microdissected samples, are often
below the critical threshold for reliable PCR analyses and
DNA modification by formaldehyde fixation significantly
worsens the prospects. For this reason, we used exclusively
cryopreserved biopsies and took care to select only cases and
samples that, by histological criteria and TCRg PCR,
contained sufficient numbers of tumor cells for safe detection
of the respective tumor MS profiles. In cases where the TCRg
PCR indicated the presence of tumor cells in the blood
(Table 3), CD8þ cells were isolated from the peripheral
blood mononuclear cells of the respective patients and used
as controls. Typically, microsatellite PCR produces a series of
fragments differing from each other by the numbers of repeat
units. Such series are generated in the PCR and represent a
single microsatellite constitution. We took the highest peaks
of these series as the lengths of the microsatellite PCR
fragment (Table 3). The smaller peaks were regarded as
‘‘stutter peaks.’’ Peaks lacking this ‘‘stutter peak’’ profile
typical for microsatellites or that were outside the size range
possible for the respective microsatellite are PCR artifacts,
and were ignored. PCR fragment sizes of tumor samples that
deviate from the fragment size found for the corresponding
control blood cell sample would indicate tumor clone-
specific mutations and be scored as MSI (Dietmaier et al.,
1997). Samples without MSI were scored as microsatellite
stable (Umar et al., 2004).
Figure 1 illustrates the case of patient 12 with patches and
plaques at the first time point considered in this study and
extensive tumors 3 years later (Figure 1a and e) with the
respective histologies (Figure 1b and f) showing the typical
features of MF at these stages, with broad dermal infiltrates
and epidermotropic lymphocytes in the patch and packed
dermal tumor cells in the tumor-stage lesion. Panels c and g
show the TCRg profiles in biopsies from these two time
points, proving the prominence of the tumor cell clone in
both infiltrates. The profile for the heterosomal DXS453 MS
PCR from the same two biopsies show the same MS pattern
for both with an MS fragment length of 159 bp (Figure 1d and
h), which is identical to what we found for CD8þ cells from
the peripheral blood of the patient (Table 3). Thus, despite the
aggressive progression of the lymphoma – the patient finally
succumbed to the disease – there is no destabilization of the
MS, and no sublineage diversification and subclone selection
detectable to correlate with the clinical course. Likewise, the
analyses of the MS fragment sizes for the four autosomal
markers D1S201, D6S260, D9S162, and D10S215 reveal
identical profiles for the normal peripheral blood cell controls
and the biopsies of tumors for patients 4, 10, and 12
(Figure 2). Also, despite aggressive progression from patch- to
tumor-stage disease within a time span of 3–4 years, the MS
were stable. Table 3 summarizes the results of the PCR for all
eight microsatellite markers and 12 patients. The MS
fragment sizes varied from patient to patient by up to 10
dinucleotide repeat units, thus illustrating considerable
polymorphism. In some of the samples biallelic amplificates
were also detected by our panel of MS markers. Despite this
natural heterogeneity, no case of altered MS profiles was
detected in a patient when peripheral blood cell controls
were compared with early- and late-stage MF lesion. The MS
were stable in all cases, although in all but one patient the
disease had progressed to advanced stage and in seven cases
even to aggressive tumor stage. In summary, in the 12
patients we tested and who, with one exception, experienced
aggressive progression of the lymphoma in the course of this
study, we did not detect any tumor cell-specific change or
even instability in the analyzed microsatellite markers.
Expression of mismatch repair genes in the MF patients
MSI in hereditary colon cancers is correlated with defects in
the expression of mismatch repair genes. To assess the
mismatch repair gene expression states in cutaneous lym-
phoma, we analyzed sections of tumor biopsies of the
advanced-stage MF patients by two-color immunofluores-
cence for CD3 (green-fluorescent cell surface staining in
Figure 3) and mismatch repair gene products (red-fluorescent
nuclear staining in Figure 3, for hMLH1). In all cases, the
expression levels of the mismatch repair genes appeared
normal and similar in both the CD3-positive and CD3-
negative cells. The example shown with Figure 3 is from a
tumor of patient 1 who had the most aggressively progressing
lymphoma of the patients analyzed. The same results were
obtained in the immunohistochemical analyses of the
biopsies of the other patients. In summary, when analyzing
the expression of hMLH1, hMSH2, hPMS2, and hMSH6 we
could not detect any loss of mismatch repair proteins in the
investigated MF lesion in our series of 12 patients. The results
of these immunofluorescence analyses are consistent with the
finding of microsatellite stability in MF tumors.
Correlation of chromosomal aberrations with microsatellite
instability
The stability of the MS markers analyzed in the present study
is in stark contrast to the large number of chromosomal
aberrations previously reported for these cancers both by our
group (Fischer et al., 2004) and by other investigators in the
Table 2. Microsatellites and chromosomal
localization of the microsatellite markers used in this
study
Marker Chromosome Expected fragment size
DXS453 Xpter-Xp21 160–183
DXS556 Xq12-Xq12 176–192
DXS1060 Xp21.1-Xp11.4 134–150
DXS418 Xp22.3-Xp22.3 142–158
D1S2011 1p32 186–204
D6S2602 6p23 159–179
D9S1622 9p22–23 172–196
D10S2151 10q22–23 152–208
1Belonging to the ‘‘CTCL-panel’’ published by Scarisbrick et al. (2003).
2Published by Ru¨bben et al. (2004).
1754 Journal of Investigative Dermatology (2007), Volume 127
C Assaf et al.
Microsatellite Instability in Mycosis Fungoides
Table 3. Microsatellite states in MF patients in the course of the disease
Case Skin lesion1 year TCRc2 DXS4533 DXS5563 DXS10603 DXS4183 D1S2013 D6S2603 D9S1623 D10S2153
1 Control p 167 186 132 141 188 173 174/184 154
P 2002 m 167 186 132 141 188 173 174/184 154
P 2004 p 167 186 132 141 188 173 174/184 154
2 Control p 167/171 184/188 139 139/144 187 157 174 159
PL 2001 p 167/171 184/188 139 139/144 187 157 174 159
T 2004 m 167/171 184/188 139 139/144 187 157 174 159
3 Control p 168 187 141 141 184/190 166 185/192 155/159
P 1999 m 168 187 141 141 184/190 166 185/192 155/159
PL 2004 m 168 187 141 141 184/190 166 185/192 155/159
4 Control p 170 187 140 140 187/193 159/169 188/190 155/168
P 1999 m 170 187 140 140 187/193 159/169 188/190 155/168
PL 2002 m 170 187 140 140 187/193 159/169 188/190 155/168
T 2005 n.d. 170 187 140 140 187/193 159/169 188/190 155/168
5 Control p 170 179 139 143 188 160/170 175 155
P 2000 m 170 179 139 143 188 160/170 175 155
T 2002 m 170 179 139 143 188 160/170 175 155
6 Control p 167 178/188 138 141/150 187 163/169 184/190 152
P 2002 m 167 178/188 138 141/150 187 163/169 184/190 152
T 2004 n.a. 167 178/188 138 141/150 187 163/169 184/190 152
7 Control b,p 170 187 143 140 190 159/170 175/187 157
P 1999 m 170 187 143 140 190 159/170 175/187 157
PL 2000 m 170 187 143 140 190 159/170 175/187 157
8 Control p 168 186 146 144 188 162/168 187 155
P 1999 m 168 186 146 144 188 162/168 187 155
PL 2003 n.a. 168 186 146 144 188 161/168 187 155
9 Control p 168 191 139 146 187 159/166 193 159
P 2000 m 168 191 139 146 187 159/166 193 159
T 2001 m 168 191 139 146 187 159/166 193 159
10 Control p 168 189 131 148 190 155 175 155
P 1999 m 168 189 131 148 190 155 175 155
T 2002 n.a. 168 189 131 148 190 155 175 155
PL 2003 b 168 189 131 148 190 155 175 155
11 Control p 159/167 178/188 132/142 138/140 189/198 160 175/184 155
P 2001 n.d. 159/167 178/188 132/142 138/140 189/198 160 175/184 155
PL 2002 m 159/167 178/188 132/142 138/140 189/198 160 175/184 155
Table 3 continued on the following page
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field (Kaltoft et al., 1992; Karenko et al., 1997, 2003; Mao
et al., 2002). Of the 12 patients in this study, tumor cells of
four had been studied by Fischer and co-workers by
comparative chromosome hybridization for chromosomal
aberrations. In two of these four cases (patients 7 and 12
corresponding to patients 27 and 25, respectively, in Fischer
et al., 2004), extensive aberrations had been found with
euchromatic losses (dim) at chromosome arms 6p, 9pq,10q,
12p, 13q, and 15q for tumor cells of patient 12, and 9q and
17p for patient 7 (Table 4). Gains of chromatin (enh) had
been found for chromosome arms 3pq, 5p, 7pq, 8q, 10p,
14q, and Xq of the tumor cells of patient 12, and 7pq and 17q
in patient 7. These results are in agreement with data from
studies with other cancers that show that chromosomal and
genomic instabilities do not correlate.
DISCUSSION
MSI is an indicator of heightened genome-wide mutation
rates that are not only expected to cause a high turnover of
tumor cells, but also to generate new tumor cell variants that
govern the evolution of the tumor from indolent to malignant
forms and may develop resistance to therapy. MSI has been
most extensively studied in hereditary colon carcinoma
associated with defects in mismatch repair genes, but has
also been reported for sporadic ovarian, prostate, and
pancreatic cancers (Bronner et al., 1994; King et al., 1995;
Rohrbach et al., 1999). The clinical evolution of MF is
characterized by extended developments as low grade and
late transformation to aggressive disease as well as by
frequent responses to various treatment modalities followed
by recurrences. The tumor cells may therefore accumulate
mutations that determine the course of the disease (Diaman-
didou et al., 1998; Kim et al., 2003). With the present
longitudinal study, we opted to assess the propensity of CTCL
toward increasing mutation rates and sublineage diversifica-
tion by analyzing the integrity of a set of eight microsatellites
at early-and late-stage disease. With one exception, all 12 MF
patients in the study had experienced progression of the
lymphoma, and seven of them were in tumor stage at the end
of the study. In all cases, we analyzed the microsatellites in
early- and late-stage tumors in comparison with non-tumor
controls of the same patients. In no case did we find a
deviation of the tumor cell MS pattern from that of the normal
cell controls, nor did we find any diversification of the MS
pattern in tumor cells advancing to malignant lymphoma. In
support of these findings, we found normal mismatch repair
gene expression in the patients.
The complete absence of MSI from the MF cases in our
study is in contrast to reports of MSI in MF by Scarisbrick
et al. (2003), and Ru¨bben et al.(2004), but it is in agreement
with the findings by Duval et al. (2004), who used consensus
microsatellite markers to study the MS in a large series of 603
cases representing various histopathological categories of
B-and T-cell non-Hodgkin lymphomas, and found only 12
cases with MSI, 2% of all patients. All 12 cases were
immunodeficiency-related lymphomas, nine post-transplan-
tation, and three HIV infection-related lymphomas. Other
investigators have reported that lymphomas with MSI are
mostly B-cell malignancies correlated with chronic immuno-
stimulation (Nagy et al., 2000; Szereday et al., 2000; Fulop
et al., 2003; Velangi et al., 2004; Niv et al., 2005). These
reports suggest that MSI-positive lymphomas may be re-
stricted to malignancies arising in the context of chronic
immune stimulation or immunodeficiency.
The discrepancy between our findings and previous
reports may be due to technical problems rather than
biological differences in the patients. Seven of the patients
in our study were in advanced tumor-stage disease at the time
the last tumor biopsies were taken for MS analysis. If MSI
does indeed occur in MF, it should have been detectable in
these samples, but it was not. The microsatellite markers
employed in our study were similar to those previously used
and, in part, chosen because they map to chromosome
regions associated with tumor suppressor genes (e.g., p53 and
PTEN). It is, therefore, unlikely that our study underestimates
the incidence of MSI in MF because of a wrong choice of
marker loci. Major technical problems known to interfere
with MS analyses are the quality of the template DNA, the
method for detecting the PCR products, and the numbers of
tumor cells in the samples used for the PCR. Often MS
analyses are performed with formaldehyde-fixed paraffin-
embedded tissue because this is the most abundantly
available in pathology departments. Formaldehyde fixation,
however, causes modification of the amino groups of the
nucleotides and can lead to DNA fragmentation. This
damage affects the suitability of the DNA as PCR template
and may impair the interpretation of the PCR results (Serth
et al., 2000). Moreover, limited numbers of tumor cells in the
Table 3. continued
Case Skin lesion1 year TCRc2 DXS4533 DXS5563 DXS10603 DXS4183 D1S2013 D6S2603 D9S1623 D10S2153
12 Control m 159 184 133 142 187/193 157 184/192 155
P 2000 m 159 184 133 142 187/193 157 184/192 155
PL 2002 m 159 184 133 142 187/193 157 184/192 155
T 2003 m 159 184 133 142 187/193 157 184/192 155
M, monoclonal amplificate; b, biallelic amplificate; n.a., no amplificate; n.d., not done; p, polyclonal amplificate.
1Control, peripheral blood mononuclear cells of the patients. P, patch; PL, plaque; T, tumor.
2TCRg diagnostic PCR.
3Size of microsatellite markers in base pairs; where two figures are given both alleles were amplified.
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sections used as source for the DNA may lead to artificial
amplificates feigning MSI. Formaldehyde fixation reduces the
amount of available template DNA and enhances the
chances of producing artifacts. To avoid such problems, it
was recommended that we work with at least 700 tumor cells
from cryopreserved sections or 1,400 tumor cells from
formaldehyde-fixed samples (Sieben et al., 2000; Diaz-Cano,
2001). In our study, we used exclusively intact high-quality
DNA from cryopreserved tumor biopsies that contained
sufficient numbers of tumor cells for the MS PCR, as
determined by histological assessment, and TCRg PCR. For
the analysis of the PCR products, we used the Genescan
technique, that is, fluorochrome-labeled PCR products were
analyzed by capillar electrophoresis in an automated DNA
sequencer. This technique is currently recommended by the
consensus criteria for determination of MSI in colorectal
cancer (Umar et al., 2004) because the detection of the PCR
products is more sensitive and the determination of the PCR
a e
b f
c
d h
g
240 260 220 240 260
140 150 160 140 150 160
Figure 1. Clinical, histological, and molecular evaluation of lesion of MF patient 12 in the clinical course of disease. (a–d) Patch/plaque stage at initial
presentation and (e–h) tumor stage. (a) Erythematous patches and plaques in the left abdominal region, (b) corresponding histology showing a broad dermal
infiltrate and epidermotropic small lymphocytes (original magnification: 100 mm), (c) Genescan profile of clonal TCRg rearrangement (252 bp), and (d) Genescan
profile of one exemplary microsatellite pattern (DXS453) showing the MS fragment size of 159 bp. (e) Multiple erythematous tumor nodules at the back and
chest. (f) Histology revealing Pautrier’s microabscesses with large atypical lymphocytes and heavy dermal infiltration (original magnification: 50mm),
(g) Genescan profile of the TCRg PCR documenting the presence of the same T-cell clone as in the initial lesion (252 bp), and (h) Genescan microsatellite pattern
(DXS453) that reproduces the pattern found for the earlier lesion with a microsatellite fragment size of 159 bp.
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fragment lengths more accurate than with autoradiography or
silver staining (Christensen et al., 1999; Dietmaier et al.,
1999).
Very often, MSI is associated with loss of expression of
mismatch repair proteins. Immunohistochemical analysis of
the expression of a panel of mismatch repair gene products is,
therefore, used as a robust measure of the potential of genetic
instability. Using the set of four mismatch repair proteins that
is currently standard in the diagnostics of hereditary colon
carcinoma (Dietmaier et al., 1997), we could not find a single
case of defective expression of these gene products among
the 12 patients analyzed in our study. However, as sparse
somatic defects in mismatch repair genes not always relate to
reduced or loss of mismatch repair protein expression,
immunohistological detection of these proteins does not
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Figure 2. Profiles of the four autosomal microsatellites in control peripheral blood cell samples and MF lesions. Representative PCR Genescan profiles of
different microsatellite loci of matched normal (above) and tumor (below) DNA from patients 4, 10, and 12.
Figure 3. Expression of mismatch repair proteins in mycosis fungoides.
Double immunofluorescence staining with hMLH1 and CD3 showing
coexpression of hMLH1 (red) and CD3 (green) in the tumor cells (sheets of
tumor cells surrounding a hair follicle) in a skin lesion of the mycosis
fungoides patient 12 at tumor stage analyzed by confocal microscopy
(original magnification: 25 mm).
Table 4. Comparison of microsatellite and
chromosomal states
Patient
number MS status CGH
1
DNA gain DNA loss
6 Stable — —
7 Stable 7q31pter, 17q11qter, 9q22q31, 17p
9 Stable —2 —
12 Stable 5q21pter, 6p14pter,
7qterp21, 8q22qter,
10p, 14q23qter,
Xq26qter
dim 5q21qter,
6p14qter, 9p23q22,
10q23qter,
12p12pter, 13,
15q22qter
CGH, comparative genomic hybridization; MS, microsatellite.
1Published data from Fischer et al. (2004)
2Represents no DNA gain or loss.
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exclude MSI. Such discrepancies have been described for
MSI-low cases (Boland et al., 1995). Notwithstanding, the
combination of normal mismatch repair gene expression and
lack of detectable MSI suggests the absence of defects in the
MMR proteins.
In the earlier studies on MSI in MF, only tumor-stage
samples (Scarisbrick et al., 2003) or microdissected material
from individual CTCL lesions (Ru¨bben et al., 2004) were
used. Here, we report a longitudinal study on the states of the
microsatellites in individual MF patients at early and late
stages of the disease. The lack of MSI in early- as well as late-
stage disease suggests that MSI has no part in the initiation
nor in the biological processes leading to transformation of
MF. These results agree with what has been found for
systemic T-cell lymphomas. In contrast, chromosomal
instability is a prominent feature of CTCL (Mao et al., 2002;
Fischer et al., 2004), as also shown for patients of the present
study. This discrepancy of microsatellite stability and
chromosomal instability is in agreement with findings
reported for other malignancies that suggest that independent
pathways and molecular mechanisms control chromosomal
and genomic integrity.
MATERIALS AND METHODS
Patients
Twelve patients with MF at the Department of Dermatology (stage
4IA) who were diagnosed by clinical, histological, immunohisto-
chemical, and molecular genetic criteria were included in the study.
For all patients, differential blood cell analysis for the CD4:CD8
ratios, peripheral blood smears for Se´zary cells, laboratory diag-
nostics, chest X-ray, and ultrasound of abdomen and peripheral
lymph nodes were performed. Visceral involvement was assessed by
imaging diagnostics and tissue and bone marrow biopsies. The
patients were staged by the TNM classification of the MF
Cooperative Group and the National Cancer Institute, USA (Bunn
and Lamberg 1979) (Table 1). Of the 12 patients, eight were male
and four were female; they ranged in age from 47 to 88 years, with a
mean of 72 years.
Histology
The skin biopsies were examined by standard hematoxylin–eosin
and immunohistochemical staining, and evaluated by the morpho-
logical and immunohistological criteria of the EORTC-WHO
classification of cutaneous lymphomas (Willemze et al., 2005).
Multiple 4 mm sections of the paraffin-embedded specimens were
examined to avoid sampling errors in histopathological staging. The
primary antibodies used for immunostaining were polyclonal anti-
CD3, clone C8-144 for CD8, clone OPD4 for CD45RO, clone Ber-
H2 for CD30 (all from DAKO, Glostrup, Denmark), clone bF1 for
T-cell receptor b chain (T Cell Sciences, Cambridge, MA), and clone
1F6 for CD4 (Novocastra, Newcastle upon Tyne, UK). For
visualization, the immunoalkaline phosphatase-anti-alkaline phos-
phatase (APAAP, DAKO, Glostrup, Denmark) enhancement techni-
que was employed (Cordell et al., 1984). For immunohistochemical
analysis of the mismatch repair proteins hMSH2, hMLH1, hMSH6,
and hPMS2, the sections were stained with the fluorochrome-labeled
mAbs FE11 (Calbiochem, San Diego, CA), G168-15 (BD Phar-
Mingen, San Diego, CA), clone 44, (Pharmingen), and clone A16-4
(Pharmingen), respectively (Ko¨lble et al., 1999; Salahshor et al.,
2001). To unmask the antigenic determinants, the samples were
subjected to high-pressure cooking in 10 mmol/l citrate buffer, pH
6.0 before the primary antibodies were applied.
TCR c PCR
All skin and peripheral blood samples were investigated for the TCR-
g rearrangements as detailed elsewhere (Lukowsky et al., 2002).
Briefly, the DNA was extracted from cryopreserved materials and
subjected to two PCRs with three Vg primers combined with two 50
fluorescence-labeled Jg primers. All PCR analyses were performed in
duplicate and only those cases with reproducible results were
regarded. The sizes of the PCR products were determined with an
automated capillary DNA sequencer (ABI 310 Prism Genetic
Analyzer, Applied Biosystems, Weiterstadt, Germany) and the
resulting data processed with the Genescan 672 software (Applied
Biosystems). The sensitivity of detection of clonal TCRg rearrange-
ments was determined by applying the above protocol to serial
admixtures of tumor cells (Jurkat or MOLT 16) to polyclonal
peripheral blood mononuclear cells and found to be between 1
and 3% clonally rearranged T cells.
Microsatellite analysis
Eight polymorphic microsatellites located on five different chromo-
somes were selected for the study: DXS418 (Xpter-Xp21), DXS453
(Xq12-Xq12), DXS556 (Xp21.1-Xp11. 4), DXS1060 (Xp22.3-
Xp22.3), D1S201 (1p32), D6S260 (6p23), D9S162 (9p22–23 located
near the CDKN2 gene), and D10S215 (10q22–23) (Table 2); all are
dinucleotide repeats. The PCRs were performed in 50ml with 0.7 ml
each of oligonucleotide primer, 4 ml 200 mM DNTP, 5ml DNA, 5ml
10 PCR-Puffer without MgCl2, 8ml 2.5 mM MgCl2, and 0.6 ml Taq
polymerase. One end of each primer pair was 50 fluorochrome
labeled (FAM). For PCR, 35–40 cycles, each for 60 seconds at 931C
for denaturation, 60 seconds at 55–601C (depending on the Tm for the
oligonucleotide primer pairs) for annealing, and 60 seconds at 721C
for extension. The sizes of the PCR products were determined with
an automated capillary DNA sequencer (ABI 310 Prism Genetic
Analyzer, Applied Biosystems, Weiterstadt, Germany) and the data
processed with the Genescan 672 software (Applied Biosystems). As
for the TCRg PCR, the sensitivity of the MS PCR was determined with
mixtures of tumor cells and peripheral blood mononuclear cells and
found to be slightly less sensitive than the former.
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